European Patent Office

T 0107/09 (CD40 counter receptor/BMS) of 12.07.2012

European Case Law Identifier
ECLI:EP:BA:2012:T010709.20120712
Date of decision
12 July 2012
Case number
T 0107/09
Petition for review of
-
Application number
93102279.2
Language of proceedings
English
Distribution
Distributed to board chairmen and members (B)
OJ versions
No OJ links found
Other decisions for this case
-
Abstracts for this decision
-
Application title
The CD40CR receptor and ligands therefor
Applicant name
Bristol-Myers Squibb Company
Trustees of Dartmouth College doing bussiness as
Dartmouth College
The General Hospital Corporation doing business as Massachusetts General Hospital
Opponent name
Biogen Idec MA Inc.
Board
3.3.04
Headnote
-
Keywords
Extension beyond the content of the application as filed (yes)
Right to priority (no) - deposit of biological material after the filing date of the earlier application
Inventive step (no)
Decisions and legal literature cited:
G 0002/93, G 0002/98, G 0001/03, T 0542/95, T 0939/92, T 0133/01, T 0512/02, T 0931/04, T 1589/05;
"In re Lundak", 773F.2d 1216, Fed.Cir. 1985
BGH X ZR 89/07 "Olanzapin"
Europäisches Patentübereinkommen: Münchner Gemeinschaftskommentar, eds.: Beier, Haertel, Schricker;
15th edition, April 1991, Art. 53, Moufang, R.
Patentgesetz mit EPÜ, ed.: Schulte, R.; 8th edition, 2008
"Notice of the European Patent Office dated 18 July 1986 concerning European patent applications and European patents in which reference is made to microorganisms", EPO OJ 1986, 269-275
"Notice from the European Patent Office dated 7 July 2010 concerning inventions which involve the use of or concern biological material", EPO OJ 2010, 498-513
Catchword
See points 6 to 26 of the Reasons
Cited cases
-

ORDER

For these reasons it is decided that:

The appeal is dismissed.